TR199701048T1 - Ba��rsak enfeksiyonlar�na kar�� ila�lar�n haz�rlanmas�nda fumagilol�n ve t�revlerinin kullan�m�. - Google Patents

Ba��rsak enfeksiyonlar�na kar�� ila�lar�n haz�rlanmas�nda fumagilol�n ve t�revlerinin kullan�m�.

Info

Publication number
TR199701048T1
TR199701048T1 TR97/01048T TR9701048T TR199701048T1 TR 199701048 T1 TR199701048 T1 TR 199701048T1 TR 97/01048 T TR97/01048 T TR 97/01048T TR 9701048 T TR9701048 T TR 9701048T TR 199701048 T1 TR199701048 T1 TR 199701048T1
Authority
TR
Turkey
Prior art keywords
fumagilol
rlanmas
revlerinin
kullan
enfeksiyonlar
Prior art date
Application number
TR97/01048T
Other languages
English (en)
Turkish (tr)
Inventor
Molina Jean-Michel
Derouin Francis
Original Assignee
Sanofi
Assistance Publique-Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi, Assistance Publique-Hopitaux De Paris filed Critical Sanofi
Publication of TR199701048T1 publication Critical patent/TR199701048T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TR97/01048T 1995-03-27 1996-03-26 Ba��rsak enfeksiyonlar�na kar�� ila�lar�n haz�rlanmas�nda fumagilol�n ve t�revlerinin kullan�m�. TR199701048T1 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27

Publications (1)

Publication Number Publication Date
TR199701048T1 true TR199701048T1 (xx) 1998-01-21

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
TR97/01048T TR199701048T1 (xx) 1995-03-27 1996-03-26 Ba��rsak enfeksiyonlar�na kar�� ila�lar�n haz�rlanmas�nda fumagilol�n ve t�revlerinin kullan�m�.

Country Status (25)

Country Link
US (1) US5900431A (2)
EP (1) EP0817626B1 (2)
JP (1) JP3260378B2 (2)
KR (1) KR100286920B1 (2)
CN (1) CN1072485C (2)
AP (1) AP646A (2)
AT (1) ATE172641T1 (2)
AU (1) AU706161B2 (2)
CA (1) CA2216623C (2)
CZ (1) CZ286821B6 (2)
DE (1) DE69600879T2 (2)
DK (1) DK0817626T3 (2)
EA (1) EA000150B1 (2)
ES (1) ES2128846T3 (2)
FR (1) FR06C0014I2 (2)
HU (1) HU224028B1 (2)
IS (1) IS2048B (2)
NO (1) NO315968B1 (2)
NZ (1) NZ304906A (2)
OA (1) OA10515A (2)
PL (1) PL183378B1 (2)
SK (1) SK283883B6 (2)
TR (1) TR199701048T1 (2)
UA (1) UA41446C2 (2)
WO (1) WO1996030010A2 (2)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP646A (en) * 1995-03-27 1998-04-27 Sanofi Synthelabo Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
ES2286998T3 (es) 1999-02-26 2007-12-16 Sanofi-Aventis Formulacion estable que contiene fumagillina.
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
CN101990441A (zh) * 2007-11-28 2011-03-23 默萨那治疗学股份有限公司 生物相容的生物可降解的烟曲霉素类似物轭合物
US8865746B2 (en) * 2008-07-18 2014-10-21 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
EP2486004B1 (en) 2009-10-09 2017-05-03 Zafgen, Inc. Sulphone compounds for use in the treatment of obesity
AU2011204267B2 (en) 2010-01-08 2015-12-03 Zafgen Corporation Fumagillol type compounds and methods of making and using same
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
CN103249735B (zh) 2010-07-22 2016-04-06 扎夫根股份有限公司 三环化合物及其制备和使用方法
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
WO2012075020A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol
KR20140006888A (ko) 2011-01-26 2014-01-16 자프겐 인크. 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
CN103534244B (zh) 2011-03-08 2016-10-12 扎夫根股份有限公司 氧杂螺[2.5]辛烷衍生物及类似物
BR112013028666A2 (pt) 2011-05-06 2017-08-08 Zafgen Inc compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
CA2835261C (en) 2011-05-06 2019-06-04 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
JP2015509102A (ja) 2012-01-18 2015-03-26 ザフゲン，インコーポレイテッド 三環式スルホン化合物並びにその作製および使用方法
MX2014008706A (es) 2012-01-18 2015-03-05 Zafgen Inc Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
US9260419B2 (en) 2012-05-07 2016-02-16 Zafgen, Inc. Polymorphic salt of a metap-2 inhibitor and methods of making and using same
AU2013259617A1 (en) 2012-05-08 2014-11-27 Zafgen, Inc. Treating hypothalamic obesity with MetAP2 inhibitors
MX356755B (es) 2012-05-09 2018-06-11 Zafgen Inc Compuestos de tipo fumagilol y metodos para su elaboración y uso.
BR112015010223A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
JP2015536981A (ja) 2012-11-05 2015-12-24 ザフゲン，インコーポレイテッド 三環式化合物ならびにその製造および使用方法
CN105228610A (zh) 2013-03-14 2016-01-06 扎夫根股份有限公司 治疗肾疾病和其它病症的方法
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
WO1992002240A2 (en) * 1990-07-27 1992-02-20 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5328930A (en) 1993-03-01 1994-07-12 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
AP646A (en) * 1995-03-27 1998-04-27 Sanofi Synthelabo Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Also Published As

Publication number Publication date
DE69600879D1 (de) 1998-12-03
HUP9801220A3 (en) 2001-10-29
NO974466L (no) 1997-09-26
SK283883B6 (sk) 2004-04-06
NO974466D0 (no) 1997-09-26
HUP9801220A2 (hu) 1999-09-28
HU224028B1 (hu) 2005-05-30
KR19980703271A (ko) 1998-10-15
WO1996030010A2 (fr) 1996-10-03
ATE172641T1 (de) 1998-11-15
CZ286821B6 (en) 2000-07-12
CA2216623C (en) 2005-05-31
PL322470A1 (en) 1998-02-02
CZ304997A3 (en) 1997-12-17
NO315968B1 (no) 2003-11-24
JPH11506421A (ja) 1999-06-08
AU706161B2 (en) 1999-06-10
EP0817626A2 (fr) 1998-01-14
MX9707150A (es) 1998-07-31
CN1072485C (zh) 2001-10-10
UA41446C2 (uk) 2001-09-17
CN1179715A (zh) 1998-04-22
EA000150B1 (ru) 1998-10-29
AU5278696A (en) 1996-10-16
DK0817626T3 (da) 1999-07-12
EA199700267A1 (ru) 1998-04-30
CA2216623A1 (en) 1996-10-03
JP3260378B2 (ja) 2002-02-25
WO1996030010A3 (fr) 1996-11-28
KR100286920B1 (ko) 2001-04-16
IS4557A (is) 1997-09-11
FR06C0014I1 (2) 2006-11-17
DE69600879T2 (de) 1999-06-02
EP0817626B1 (fr) 1998-10-28
IS2048B (is) 2005-09-15
NZ304906A (en) 1999-06-29
US5900431A (en) 1999-05-04
SK130797A3 (en) 1998-03-04
OA10515A (fr) 2002-04-24
AP9701092A0 (en) 1997-10-31
ES2128846T3 (es) 1999-05-16
FR06C0014I2 (2) 2006-12-29
AP646A (en) 1998-04-27
PL183378B1 (pl) 2002-06-28

Similar Documents

Publication Publication Date Title
BR8802237A (pt) Sistema gerador de arco e sistema gerador de gas ionizado
AR038429A2 (es) Compuestos 15-alquil-16-hidroxilo de marcfortina
NO893400D0 (no) Hiv protease inhibitorer egnet for behandling av aids.
DE69104777D1 (de) Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen.
EE9800070A (et) Vehiikulitena kasutatavad mikroemulsioonid toimivate ühendite manustamiseks
MX9205725A (es) Formulaciones generantes de gas no azidico
FI955315L (fi) HIV:n proteaasin inhibiittoreita, jotka ovat käyttökelpoisia AIDS'n hoitoon
EP0676954A4 (en) HIV LOCK VIRUS.
FI981591A7 (fi) AIDS:n hoidossa käyttökelpoisia HIV-proteaasi-inhibiittoreita
DE69002720D1 (de) Zuendverstaerkeranlage bei gasfackel.
ATE74804T1 (de) Verringerung des durchmessers von rohrfoermigen koerpern.
DE68901043D1 (de) Waessriges pharmazeutisches praeparat.
ES2079402T3 (es) Un proceso para la preparacion de hidrocloruro de ester metilico de alfa-l-aspartil-l-fenilalanina mediante el uso de anhidrido n-formil-aspartico aislado.
TR199801196T2 (xx) Biyolojik aktif benzotiyazolon etanaminler.
IT8322485A0 (it) Procedimento e dispositivo perl'azionamento e la sincronizzazione di rulli.
IL110967A0 (en) Substituted tetronic acids useful for treating hiv and other retroviruses
DK0815141T3 (da) Antistof mod et fusionspolypeptid omfattende en histidinandel
ES2049711T3 (es) Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de cistinuria.
SI0817786T1 (en) Substituted tetronic acids useful for treating hiv and other retroviruses
IE780132L (en) Tetrazole derivatives
IT8941620A0 (it) Metodo di saldatura sopratesta ad arco sommerso e dispositivo per la sua realizzazione.
HU9201976D0 (en) Medical preparative inhibiting production of active lymphocytes
ITBS910137A1 (it) Vaporizzatore ad arco voltaico
FR2691359B1 (fr) Nouvelle application therapeutique du malate de 1-citrulline.
IT1233366B (it) Dispositivo per la saldatura sopratesta ad arco sommerso.